BRIDGEWATER, N.J., and BENGALURU, India – October 16, 2025: Biocon Biologics Ltd., a global leader in biosimilars, has expanded its strategic collaboration with Civica, Inc. to launch private-label Insulin Glargine in the United States, aiming to broaden access to high-quality, affordable diabetes treatments for 38.4 million Americans living with diabetes.
Science Significance
This launch represents a major advancement in biosimilar insulin therapy, with Insulin Glargine-yfgn approved by the U.S. FDA as an interchangeable biosimilar. The partnership ensures continuous supply of basal insulin, supporting improved glycemic control in both adult and pediatric patients, and highlights innovation in biopharmaceutical manufacturing without technology transfer, retaining Biocon’s proprietary IP.
Regulatory Significance
The collaboration leverages Biocon Biologics’ existing FDA-approved marketing authorization, while Civica commercializes under a private label agreement, ensuring compliance with U.S. regulatory standards. Insulin Glargine-yfgn adheres to stringent safety and efficacy requirements, including clear contraindications, monitoring guidance, and risk management measures, aligning with cGxP quality principles.
Business Significance
Advertisement
This multi-year, transformational partnership establishes an exclusive distributorship, expanding Biocon’s market reach and allowing Civica to bring transparent, low-cost insulin to underserved populations. Biocon continues direct commercialization of its own insulin products, reinforcing its position as the fourth largest insulin provider globally with a portfolio exceeding 9.2 billion doses.
Patients’ Significance
By increasing availability of affordable insulin, the initiative addresses the urgent need for accessible diabetes care. It provides alternatives for patients facing barriers to treatment, enhances continuity of care, and targets prediabetic populations at risk, ultimately improving health outcomes and quality of life.
Policy Significance
The partnership aligns with broader U.S. healthcare priorities, promoting affordable medication access, enhancing competition in the insulin market, and supporting policy initiatives aimed at reducing drug cost burdens for chronic conditions.
The Biocon-Civica collaboration underscores the importance of strategic partnerships in advancing pharmaceutical innovation, regulatory compliance, and patient-centric care. With the launch of private-label Insulin Glargine, the U.S. market gains a reliable, high-quality biosimilar option, exemplifying how global biosimilar leaders can transform diabetes treatment accessibility and affordability.
Source: Biocon Biologics Ltd. press release
